These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18239059)

  • 1. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases.
    Pacher P; Gao B
    Am J Physiol Gastrointest Liver Physiol; 2008 Apr; 294(4):G850-4. PubMed ID: 18239059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.
    Huang L; Quinn MA; Frampton GA; Golden LE; DeMorrow S
    Dig Liver Dis; 2011 Mar; 43(3):188-93. PubMed ID: 20934397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocannabinoids in liver disease.
    Tam J; Liu J; Mukhopadhyay B; Cinar R; Godlewski G; Kunos G
    Hepatology; 2011 Jan; 53(1):346-55. PubMed ID: 21254182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.
    Mallat A; Lotersztajn S
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G9-G12. PubMed ID: 17975129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.
    Pertwee RG
    AAPS J; 2005 Oct; 7(3):E625-54. PubMed ID: 16353941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocannabinoids, cannabinoid receptors and inflammatory stress: an interview with Dr. Pál [corrected] Pacher. Interviewed by Helene F. Rosenberg.
    Pacher PA
    J Leukoc Biol; 2007 Dec; 82(6):1390-2. PubMed ID: 18040082
    [No Abstract]   [Full Text] [Related]  

  • 7. Endocannabinoids signaling: Molecular mechanisms of liver regulation and diseases.
    Wang M; Meng N; Chang Y; Tang W
    Front Biosci (Landmark Ed); 2016 Jun; 21(7):1488-501. PubMed ID: 27100518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocannabinoid overactivity and intestinal inflammation.
    Di Marzo V; Izzo AA
    Gut; 2006 Oct; 55(10):1373-6. PubMed ID: 16966693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings.
    Mallat A; Teixeira-Clerc F; Deveaux V; Manin S; Lotersztajn S
    Br J Pharmacol; 2011 Aug; 163(7):1432-40. PubMed ID: 21457226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of the endocannabinoid system in cardiovascular disease.
    Pacher P; Steffens S
    Semin Immunopathol; 2009 Jun; 31(1):63-77. PubMed ID: 19357846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
    Pacher P; Haskó G
    Br J Pharmacol; 2008 Jan; 153(2):252-62. PubMed ID: 18026124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis.
    Caraceni P; Viola A; Piscitelli F; Giannone F; Berzigotti A; Cescon M; Domenicali M; Petrosino S; Giampalma E; Riili A; Grazi G; Golfieri R; Zoli M; Bernardi M; Di Marzo V
    Liver Int; 2010 Jul; 30(6):816-25. PubMed ID: 19840245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: the endocannabinoid system in liver disease, a potential therapeutic target.
    Basu PP; Aloysius MM; Shah NJ; Brown RS
    Aliment Pharmacol Ther; 2014 Apr; 39(8):790-801. PubMed ID: 24612021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders.
    Bisogno T; Di Marzo V
    CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):564-73. PubMed ID: 20632970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.
    Bátkai S; Mukhopadhyay P; Harvey-White J; Kechrid R; Pacher P; Kunos G
    Am J Physiol Heart Circ Physiol; 2007 Sep; 293(3):H1689-95. PubMed ID: 17557913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocannabinoids and their role in fatty liver disease.
    Mallat A; Lotersztajn S
    Dig Dis; 2010; 28(1):261-6. PubMed ID: 20460921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue.
    Marquéz L; Suárez J; Iglesias M; Bermudez-Silva FJ; Rodríguez de Fonseca F; Andreu M
    PLoS One; 2009 Sep; 4(9):e6893. PubMed ID: 19730730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
    Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
    Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The endocannabinoid system in cholestasis.
    Floreani A; Pizzuti D; Bergasa NV; Petrosino S
    Dig Liver Dis; 2011 Dec; 43(12):1026-7. PubMed ID: 21816694
    [No Abstract]   [Full Text] [Related]  

  • 20. Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states.
    Karanian DA; Bahr BA
    Curr Mol Med; 2006 Sep; 6(6):677-84. PubMed ID: 17022737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.